Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€43.81
27.02.20
€58.00
04.11.21
0.70%
03.06.21

buy
Bayer AG

Start price
Target price
Perf. (%)
€56.10
19.05.21
€80.00
19.11.21
-1.41%
26.05.21

Revenue growth > 30% per year expected
Undervalued
High Investments for future growth
Top Rating
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€3.70
02.05.21
-
02.05.22
1.08%
16.05.21

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Haemato AG

Start price
Target price
Perf. (%)
€28.90
02.05.21
€35.00
02.05.22
-4.50%
15.05.21

Could be worthwhile Investment >10% per year
Future proof or reliable business model
buy
Eckert & Ziegler Strahlen- und Medizintechnik AG

Start price
Target price
Perf. (%)
€73.50
15.04.21
€88.00
15.04.22
10.48%
03.05.21

Could be worthwhile Investment >10% per year
buy
CytoTools AG

Start price
Target price
Perf. (%)
€10.20
12.08.20
€26.00
04.11.21
56.86%
13.04.21

Could be very worthwhile Investment >20% year
Differentiated customer and product portfolio
buy
Evotec SE

Start price
Target price
Perf. (%)
€25.50
29.11.20
-
29.11.21
20.04%
24.03.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
buy
Merck KGaA

Start price
Target price
Perf. (%)
€141.75
17.02.21
€150.00
1.98%
23.03.21

buy
Evotec SE

Start price
Target price
Perf. (%)
€23.57
19.10.20
-
04.11.21
25.20%
11.03.21

Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
buy
Formycon AG

Start price
Target price
Perf. (%)
€65.20
12.12.20
-
12.12.21
-7.06%
11.03.21

Could be worthwhile Investment >10% per year
buy
Evotec SE

Start price
Target price
Perf. (%)
€28.90
06.01.21
€40.00
-1.18%
10.03.21

Medium risks for its business
buy
Bayer AG ADR

Start price
Target price
Perf. (%)
€13.10
08.03.21
€14.00
3.05%
10.03.21

EBIT growth >5% per year expected
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Higher EBIT margin than peer group
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€4.22
21.02.21
-
21.02.22
-5.21%
06.03.21

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Evotec SE

Start price
Target price
Perf. (%)
€26.01
13.02.20
€35.00
04.11.21
27.91%
27.02.21

Revenue growth >5% per year expected
Fair valuation
Capable Management
buy
Medigene AG

Start price
Target price
Perf. (%)
€3.56
18.12.20
-
18.12.21
8.86%
27.02.21

Innovative
Dependend from some customers or products
Higher risks for its business
buy
Bayer AG

Start price
Target price
Perf. (%)
€46.63
12.12.20
-
12.12.21
17.84%
16.02.21

Higher risks for its business
Increased challenges to pay loans and raise capital
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€37.03
29.01.21
€34.00
29.04.21
-5.94%
08.02.21

Could be worthwhile Investment >10% per year
Fair valuation
High dividend yield expected
Small challenges to pay loans and raise capital
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€33.80
02.02.21
€30.00
16.02.21
0.27%
02.02.21

buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€37.29
21.12.20
€42.00
-3.06%
01.02.21

buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€39.13
11.01.21
€50.00
11.01.22
-5.37%
29.01.21

Could be worthwhile Investment >10% per year
Fair valuation
High dividend yield expected
Small challenges to pay loans and raise capital
buy
Evotec SE

Start price
Target price
Perf. (%)
€24.26
09.11.20
-
09.11.21
21.35%
14.01.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€4.36
13.12.20
-
13.12.21
-5.96%
10.01.21

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
MorphoSys AG

Start price
Target price
Perf. (%)
€17.70
03.07.12
€124.00
04.11.21
419.77%
08.12.20

Merck KGaA

Start price
Target price
Perf. (%)
€124.80
23.09.20
-
04.11.21
4.17%
25.11.20

ROE higher than 10% per year
Low dividend yield expected
buy
Bayer AG

Start price
Target price
Perf. (%)
€44.22
14.10.20
€47.00
04.11.21
8.47%
11.11.20

Undervalued
Risky Investment